for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cytosorbents Corp

CTSO.OQ

Latest Trade

5.50USD

Change

0.11(+2.04%)

Volume

29,962

Today's Range

5.36

 - 

5.51

52 Week Range

3.68

 - 

13.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.39
Open
5.37
Volume
29,962
3M AVG Volume
3.63
Today's High
5.51
Today's Low
5.36
52 Week High
13.90
52 Week Low
3.68
Shares Out (MIL)
32.30
Market Cap (MIL)
174.11
Forward P/E
-10.33
Dividend (Yield %)
--

Latest Developments

More

Cytosorbents Reports Q2 Revenue $6.233 Million

Cytosorbents Qtrly Loss Per Share $0.15

Israel Approves Cytosorb Registration

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cytosorbents Corp

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.

Industry

Medical Equipment & Supplies

Contact Info

7 Deerpark Dr Ste K

http://cytosorbents.com/

Key Stats

2.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.470

2017

-0.320

2018

-0.560

2019(E)

-0.522
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.49
Price To Book (MRQ)
15.08
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
86.54
LT Debt To Equity (MRQ)
79.32
Return on Investment (TTM)
-63.52
Return on Equity (TTM)
-53.10

Latest News

BRIEF-Cytosorb Adds Bilirubin And Myoglobin Reduction To Eu Approved Indications For Use

* CYTOSORB® ADDS BILIRUBIN AND MYOGLOBIN REDUCTION TO EUROPEAN UNION APPROVED INDICATIONS FOR USE

BRIEF-CytoSorbents Reports Qtrly Loss Per Share $0.10

* CYTOSORBENTS REPORTS STRONG FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Cytosorbents Enrolls First Patient Into Pivotal U.S. Refresh 2-AKI Trial

* CYTOSORBENTS ENROLLS FIRST PATIENT INTO PIVOTAL U.S. REFRESH 2-AKI TRIAL USING CYTOSORB® DURING COMPLEX CARDIAC SURGERY Source text for Eikon: Further company coverage:

BRIEF-Cytosorbents Refinances Existing Debt With New $15 Mln Debt Facility With Bridge Bank

* CYTOSORBENTS REFINANCES EXISTING DEBT WITH NEW $15 MILLION DEBT FACILITY WITH BRIDGE BANK

BRIEF-Cytosorbents Achieves Record Revenue And Product Sales Growth In 2017

* CYTOSORBENTS ACHIEVES RECORD REVENUE AND PRODUCT SALES GROWTH IN 2017

BRIEF-Cytosorbents Expands Its Partnership With Biocon To Launch Cytosorb In Malaysia

* CYTOSORBENTS EXPANDS ITS PARTNERSHIP WITH BIOCON TO LAUNCH CYTOSORB® IN MALAYSIA

BRIEF-Cytosorbents Sees Q4 2017 Revenue About $4.6 Million

* CYTOSORBENTS PRE-ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND ISSUES STOCKHOLDER LETTER

BRIEF-U.S. FDA Approves Cytosorbents' Refresh 2 IDE Application With Conditions

* CYTOSORBENTS ACHIEVES KEY MILESTONE WITH FDA APPROVAL OF THE U.S. REFRESH 2 PIVOTAL CARDIAC SURGERY TRIAL IDE APPLICATION

BRIEF-Cytosorbents posts Q3 revenue of $3.8 mln

* Cytosorbents continues strong trajectory of growth in the third quarter 2017

BRIEF-CytoSorbents says partnered with DRGR to expand sales, distribution of cytosorb to Panama

* CytoSorbents says partnered with Droguería Ramón González Revilla (DRGR) to expand sales and distribution of cytosorb to panama

BRIEF-CytoSorbents receives additional $5 mln in non-dilutive debt financing from Bridge Bank

* CytoSorbents receives additional $5 million in non-dilutive debt financing from Bridge Bank

BRIEF-Cytosorbents, Aferetica renew partnership

* Cytosorbents - co, Aferetica SRL renew partnership enabling Aferetica to exclusively distribute Cytosorb in Italy through 2021

BRIEF-Cytosorbents qtrly loss per share $0.05

* Continue to expect our Q2 2017 product sales to exceed sales reported in Q2 of 2016

BRIEF-Cytosorbents reports positive refresh i trial results

* Cytosorbents Corp- achieved primary safety endpoint of study with a favorable adjudication of all serious adverse events Source text for Eikon: Further company coverage:

BRIEF-Cytosorbents announces pricing of follow-on offering

* Cytosorbents Corp - pricing of an underwritten public offering of 2.2 million shares of its common stock at a public offering price of $4.50 per share Source text for Eikon: Further company coverage:

BRIEF-Cytosorbents announces proposed offering of common stock

* Cytosorbents - Intends to use net proceeds from offering partly for advancing U.S. pivotal trial for treatment of inflammation in conjunction with cardiac surgery Source text for Eikon: Further company coverage:

BRIEF-Cytosorbents Corp enters into a partnership with Dr. Reddy's laboratories

* Have entered into a partnership with Dr. Reddy's laboratories ltd for South African market

BRIEF-Cytosorbents FY loss per share $0.47

* Cytosorbents reports record quarterly and full-year 2016 revenue

BRIEF-Cytosorbents launches VetResQ for U.S. veterinary market

* Cytosorbents launches VetResQ for U.S. veterinary market Source text for Eikon: Further company coverage:

BRIEF-Cytosorbents and Fresenius Medical Care agree to broaden terms of existing partnership

* Fresenius Medical Care, Cytosorbents agreed to broaden terms of existing partnership,to add expansive co-marketing deal for Cytosorb

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up